CNBC Television U.K. approves Pfizer-BioNTech coronavirus vaccine to begin rolling out next week

🎯 Загружено автоматически через бота: 🚫 Оригинал видео: 📺 Данное видео принадлежит каналу «CNBC Television» (@CNBCtelevision). Оно представлено в нашем сообществе исключительно в информационных, научных, образовательных или культурных целях. Наше сообщество не утверждает никаких прав на данное видео. Пожалуйста, поддержите автора, посетив его оригинальный канал. ✉️ Если у вас есть претензии к авторским правам на данное видео, пожалуйста, свяжитесь с нами по почте support@, и мы немедленно удалим его. 📃 Оригинальное описание: The U.K. on Wednesday authorized the Pfizer-BioNTech vaccine for emergency use, marking another step in the global battle against the pandemic. The vaccine will now be rolled out in the country next week, with elderly people in care homes and medical workers first in line. Julianna Tatelbaum reports. For access to live and exclusive video from CNBC subscribe to CNBC PRO: The U.K. on Wednesday became the first country to authorize the Pfizer-BioNTech vaccine for emergency use, marking another step in the global battle against the pandemic. The vaccine will now be rolled out in the country next week, with elderly people in care homes and medical workers first in line. The U.K. government is the first in the world to formally approve the vaccine for widespread use, and it means Britain will be one of the first countries to begin vaccinating its population. Emergency use approval in the United States is under review by the Food and Drug Administration. “The government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech’s Covid-19 vaccine for use,” the government said Wednesday. “The vaccine will be made available across the U.K. from next week.” Pfizer’s Chairman and CEO, Dr. Albert Bourla, said the authorization was a “historic moment.” “This authorization is a goal we have been working toward since we first declared that science will win, and we applaud the MHRA for their ability to conduct a careful assessment and take timely action to help protect the people of the U.K.,” he said. “With thousands of people becoming infected, every day matters in the collective race to end this devastating pandemic.” Pfizer and BioNTech announced in July an agreement with the U.K. to supply 30 million doses of its mRNA-based vaccine, formally known as BNT162b2, once authorized for emergency use. That agreement was increased to 40 million doses in early October. As a two-dose vaccine, the U.K. will have enough doses to vaccinate around a third of its 66 million population. BioNTech said Wednesday that the delivery of the 40 million doses will occur throughout 2020 and 2021, with complete delivery fulfilment expected next year. A spokesman for the U.K.’s Department of Health and Social Care said it would soon be known which parts of the population would be the first to receive the vaccine. “The Joint Committee on Vaccinations and Immunisations will shortly publish its final advice for the priority groups to receive the vaccine, including care home residents, health and care staff, the elderly and the clinically extremely vulnerable,” he said. The U.K.’s approval of the Pfizer vaccine, which was seen to be 95% effective at preventing Covid-19 in late-stage clinical trials, has prompted questions over when we could see regulators in the rest of Europe, and the U.S., make their respective decisions on whether to authorize the vaccine. On Monday, Pfizer and BioNTech said they had applied to the European Medicines Agency for the conditional marketing authorization of the vaccine. If the authorization is granted, it could enable use of the vaccine in Europe this month, BioNTech said, although the EMA later said on Tuesday that it would complete its review of the vaccine by Dec. 29. For its part, the Food and Drug Administration said in late November that it had scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee on Dec. 10 to discuss Pfizer and BioNTech’s request for the emergency use authorization of its vaccine, so a decision could be announced soon after. » Subscribe to CNBC TV: » Subscribe to CNBC: » Subscribe to CNBC Classic: Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: Connect with CNBC News Online Get the latest news: